Benefits of antihypertensive drugs when blood pressure is below 140/90 mmHg

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 9, 2011, Pages 303-308

  Izzo Jr , Joseph L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Antihypertensive drugs; Outcomes; Prehypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LOSARTAN; OLMESARTAN; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT;

ATTRIBUTABLE RISK; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MICROALBUMINURIA; MORTALITY; OBSERVATIONAL STUDY; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 80053368253     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Izzo JL Jr. Are there benefits of antihypertensive therapy beyond blood pressure lowering? Curr Hypertens Rep. 2010; 12: 440-447.
2. Jamerson K, Weber MA, Bakris GL, et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417-2428.
3. Izzo JL. Lessons from the ACCOMPLISH trial. Pol Arch Med Wewn. 2009; 119: 344-346.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
5. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114: 555-576.
6. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25: 305-313.
7. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 Express. JAMA. 2003; 289: 2560-2572. (Pubitemid 37430158)
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007; 28: 1462-1536.
9. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009; 18: 308-347.
10. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. Am J Cardiol. 1971; 27: 335-346.
11. Neaton JD, Wentworth D, Group MR. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992; 152: 56-64.
12. Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case?control study. Lancet. 2004; 364: 937-952. (Pubitemid 39208455)
13. Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35: 1021-1024. (Pubitemid 30327249)
14. Lewington S, Clarke R, Qizilbash N, et al.; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta?analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360: 1903-1913. (Pubitemid 35472129)
15. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334: 13-18. (Pubitemid 26012498)
16. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin?receptor blocker. New Engl J Med. 2006; 354: 1685-1697.
17. Luders S, Schrader J, Berger J, et al.; PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high?normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008; 26: 1487-1496.
18. Elmer PJ, Obarzanek E, Vollmer WM, et al.; PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18?month results of a randomized trial. Ann Intern Med. 2006; 144: 485-495. (Pubitemid 46780671)
19. Haller H, Ito S, Izzo JL Jr, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med. 2011; 364: 907-917.
20. De Galan BE, Perkovic V, Ninomiya T, et al.; ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009; 20: 883-892.
21. Arima H, Chalmers J, Woodward M, et al.; PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006; 24: 1201-1208. (Pubitemid 43772329)
22. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. New Engl J Med. 2009; 361: 40-51.
23. Lloyd-Jones DM. Ischemic heart disease risk. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer. Dallas, TX: American Heart Association; 2008: 249-253.
24. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first?ever and recurrent) stroke. Stroke. 1999; 30: 2523-2528.
25. O'Connell JB. The economic burden of heart failure. Clin Cardiol. 2000; 23 (3 Suppl): III6-10.
26. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end?stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001; 12: 2753-2758. (Pubitemid 33115423)
27. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991; 265: 3255-3264.
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003. (Pubitemid 34286536)
29. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. New Engl J Med. 2008; 358: 1887-1898. (Pubitemid 351620109)
30. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta?analysis. Lancet. 2001; 358: 1305-1315. (Pubitemid 33016494)
31. Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension. 2005; 45: 907-913. (Pubitemid 40628936)
32. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005; 28: 385-407. (Pubitemid 41014801)
33. Leenen FH. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. Can J Cardiol. 2004; 20 Suppl B: 77B-82B.
34. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007; 115: 2761-2788. (Pubitemid 46842793)
35. Greenberg JA. Removing confounders from the relationship between mortality risk and systolic blood pressure at low and moderately increased systolic blood pressure. J Hypertens. 2003; 21: 49-56. (Pubitemid 36143508)
36. Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J?curves. Am J Epidemiol. 2007; 166: 824-831. (Pubitemid 47428899)
37. Sleight P, Redon J, Verdecchia P, et al.; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009; 27: 1360-1369.
38. Messerli FH, Panjrath GS. The J?curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol. 2009; 54: 1827-1834.
39. Smulyan H, Safar ME. The diastolic blood pressure in systolic hypertension. Ann Intern Med. 2000; 132: 233-237. (Pubitemid 30064924)
40. Kannel WB, Wilson PW, Nam BH, et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol. 2004; 94: 380-384. (Pubitemid 38962714)
41. Ninomiya T, Perkovic V, Gallagher M, et al.; PROGRESS Collaborative Group. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int. 2008; 73: 963-970. (Pubitemid 351458323)
42. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension. 1997; 30: 428-435. (Pubitemid 27446104)
43. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288: 2421-2431. (Pubitemid 35340538)
44. Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 830-837.
45. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta?analysis. JAMA. 2011; 305: 913-922.